COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM).

Michael A. Davies(The University of Texas MD Anderson Cancer Center), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Keith T. Flaherty(Cancer Research Center), Célèste Lebbé(Inserm), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Thierry Lesimple, Stergios J. Moschos(University of North Carolina at Chapel Hill), Jean‐Jacques Grob(Aix-Marseille Université), David Hogg(University of Leeds), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Georgina V. Long(The University of Sydney), Laurent Mortier, L. Thomas(University of Liverpool), Bijoyesh Mookerjee(Novartis (United States)), Ying Zhang(Beijing Forestry University), Caroline Robert(Institut Gustave Roussy), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Yingjie Huang, Ana Arance(Hospital Clínic de Barcelona)

Journal of Clinical Oncology

May 20, 2017

Cited by 10

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.9k

|New England Journal of Medicine|2014|5.3k

|Science|2016|5.3k

|Journal of Clinical Oncology|2009|4.6k

COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600–mutant (mut) melanoma brain metastases (MBM).